Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Friday . The company traded as low as $9.00 and last traded at $9.19, with a volume of 261280 shares traded. The stock had previously closed at $9.22.
Astellas Pharma Stock Performance
The stock has a fifty day moving average of $9.73 and a 200-day moving average of $10.37. The firm has a market capitalization of $16.63 billion, a P/E ratio of -41.77 and a beta of 0.29. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, research analysts anticipate that Astellas Pharma Inc. will post 0.42 EPS for the current year.
About Astellas Pharma
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
- Five stocks we like better than Astellas Pharma
- How to start investing in penny stocks
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- When to Sell a Stock for Profit or Loss
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- How to Effectively Use the MarketBeat Ratings Screener
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
